



**Limited Review Report on Quarterly unaudited Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Review Report to the Board of Directors,  
Indrayani Biotech Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **Indrayani Biotech Limited** ('the Company') for the quarter ended September 30 2019. This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Venkatesh & Co  
Chartered Accountants  
F.R.No.004636S**

**CA Dasaraty V  
Partner  
M.No.026336**



**Place : Chennai  
Date : 14<sup>th</sup> November 2019.  
UDIN:- 19026336AAAAGG4738**

**M/s. INDRAYANI BIOTECH LIMITED**

CIN:L40100TN1992PLC129301 Website: www.indrayani.com

41/23 Parameshwari Nagar 1st Street, Adayar, Chennai 600020

**Balance sheet as at 30th September 2019**

**(in Rs.Lakhs)**

<i>Particulars</i>	<i>Notes</i>	<i>30-Sep-19</i>	<i>31-Mar-19</i>
<b>ASSETS</b>			
<b>A) Non - Current Assets</b>			
a) Property Plant and Equipment		-	-
b) Capital Work in Progress		-	-
c) Goodwill		-	-
d) Other Intangible assets		-	-
e) Financial Assets			
--- (i) Investments		-	-
--- (ii) Loans		-	-
f) Other Non Current assets		-	-
<b>B) Current Assets</b>			
a) Inventories		-	-
b) Financial Assets			
--- (i) Investments		-	-
--- (ii) Trade Receivables		-	-
--- (iii) Cash and cash Equivalents	3	0.248	0.562
c) Other Current assets		12.720	-
<b>Total Assets</b>		<b>12.968</b>	<b>0.562</b>
<b>EQUITY &amp; LIABILITIES</b>			
<b>A) Equity</b>			
a) Equity Share Capital	4	364.386	364.386
b) Other Equity		-442.738	-429.910
<b>B) LIABILITIES</b>			
<b>Non - Current Liabilities</b>			
a) Financial Liabilities			
--- (i) Borrowings	5	66.748	64.189
--- (ii) Other financial Liabilities		-	-
b) Other Non Current Liabilities		-	-
<b>Current Liabilities</b>			
a) Financial Liabilities			
--- (i) Trade Payables		-	-
----- (A) total outstanding dues of micro enterprises and small enterprises;		-	-
----- (B) total outstanding dues of creditors other than micro enterprises and small enterprises	6	0.572	0.755
--- (ii) Other financial Liabilities		-	-
b) Other Current Liabilities		24.000	-
c) Provisions	7	-	1.142
<b>Total Equity &amp; Liabilities</b>		<b>12.968</b>	<b>0.562</b>

**FOR INDRAYANI BIOTECH LIMITED**

Place: Chennai

Date: 14.11.2019



*K. Sayeesundar*

**K SAYEESUNDAR  
MANAGING DIRECTOR**

**DIN:01295584**

<b>INDRAYANI BIOTECH LIMITED</b> Regd. Office : 41(23) Parameswari Nagar First Street, Adyar Chennai-600020 CIN:L40100TN1992PLC129301 Website:www.indrayani.com <b>UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTMBER 2019</b> <b style="float: right;">Rs. In Lakhs</b>					
	PARTICULARS	QUARTER ENDED			
Sr No	PARTICULARS	3 months ended 30/09/2019	Corresponding 3 months ended in the previous year 30/09/2018	Year to date figures for current period ended 30/09/2019	Previous Year ended 31/03/2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>A</b>	Date of start of reporting period	01/07/2019	01/07/2018	01/04/2019	01/04/2018
<b>B</b>	Date of end of reporting period	30/09/2019	30/09/2018	30/09/2019	31/03/2019
<b>C</b>	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>D</b>	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
<b>1</b>	<b>Income from Operations</b>				
	(a) Net Sales/Revenue from Operations	0.000	0.000	0.000	0.000
	(b) Other Income	0.000	0.000	0.000	16.110
	<b>Total Income from Operations</b>	0.000	0.000	0.000	<b>16.110</b>
<b>2</b>	<b>Expenses</b>				
	(a) Cost of Materials consumed	0.000	0.000	0.000	0.000
	(b) Purchase of stock-in-trade	0.000	0.000	0.000	0.000
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.000	0.000	0.000	0.000
	(d) Employee benefits expenses	1.500	0.900	1.500	3.300
	(e) Finance Costs	1.247	0.000	2.494	0.010
	(f) Depreciation and amortisation expense	0.000	0.000	0.000	0.000
	(g) Other expenses				
	- Advertisement	0.324	0.540	0.366	1.991
	- Audit Fees	0.000	0.000	0.000	1.500
	- Business Promotion	0.000	0.020	0.000	0.020
	- Legal & Professional Expenses	1.968	3.480	3.523	13.023
	- Rates & Taxes	0.000	0.000	3.540	0.030
	- Telephone & Postage	0.000	0.000	0.000	0.000
	- Travelling & Conveyance	0.575	0.000	1.368	0.634
	- Filing Fees & Subscription	0.000	0.120	0.000	0.210
	- Printing & Stationery	0.000	0.000	0.000	0.500
	- Postage & Courier	0.000	0.000	0.000	0.010
	- Interest and Finance charges	0.003	0.000	0.000	0.000
	- Bank Charges	0.037	0.000	0.037	0.000
	Total Other expenses	2.907	4.160	8.834	18.180
	<b>Total Expenses</b>	<b>5.654</b>	<b>5.060</b>	<b>12.828</b>	<b>21.490</b>
<b>3</b>	<b>Total profit / (Loss) before exceptional items and tax</b>	-5.654	-5.060	-12.828	-5.380
<b>4</b>	Exceptional Items	0.000	0.000	0.000	0.000
<b>5</b>	<b>Total profit / (Loss) before tax</b>	-5.654	-5.060	-12.828	-12.030
<b>7</b>	<b>Tax Expenses</b>				
<b>8</b>	Current Tax	0.000	0.000	0.000	0.000
<b>9</b>	Deferred Tax	0.000	0.000	0.000	0.000
<b>10</b>	<b>Total Tax Expenses</b>	0.000	0.000	0.000	0.000

11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.000	0.000	0.000	0.000
14	<b>Net Profit Loss for the period from continuing operations</b>	-5.654	-5.060	-12.828	-12.030
15	<b>Profit (loss) from discontinued operations before tax</b>	0.000	0.000	0.000	0.000
16	<b>Tax expense of discontinued operations</b>	0.000	0.000	0.000	0.000
17	<b>Net profit (loss) from discontinued operation after tax</b>	0.000	0.000	0.000	0.000
19	<b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>	0.000	0.000	0.000	0.000
21	<b>Total profit (loss) for period</b>	-5.654	-5.060	-12.828	-12.030
22	<b>Other comprehensive income net of taxes</b>	0.000	0.000	0.000	0.000
23	<b>Total Comprehensive Income for the period</b>	0.000	0.000	0.000	0.000
24	<b>Total profit or loss, attributable to</b>				
	Profit or loss, attributable to owners of parent	-5.654	-5.060	-12.828	-12.030
	Total profit or loss, attributable to non-controlling interests	0.000	0.000	0.000	0.000
25	<b>Total Comprehensive income for the period attributable to</b>				
	Comprehensive income for the period attributable to owners of parent	0.000	0.000	0.000	0.000
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests	0.000	0.000	0.000	0.000
26	<b>Details of equity share capital</b>				
	Paid-up equity share capital	364.386	364.386	364.386	364.386
	Face value of equity share capital	10.000	10.000	10.000	10.000
27	<b>Details of debt securities</b>				
	Paid-up debt capital	0.000		0.000	0.000
	Face value of debt securities	0.000		0.000	0.000
28	<b>Reserves excluding revaluation reserve</b>	0.000		0.000	0.000
29	<b>Debenture redemption reserve</b>	0.000		0.000	0.000
30	<b>Earnings per share</b>				
i	<b>Earnings per equity share for continuing operations</b>				
	Basic earnings (loss) per share from continuing operations	-0.155	-0.139	-0.352	-0.330
	Diluted earnings (loss) per share from continuing operations	-0.155	-0.139	-0.352	-0.330
ii	<b>Earnings per equity share for discontinued operations</b>				
	Basic earnings (loss) per share from discontinued operations	0.000	0.000	0.000	0.000
	Diluted earnings (loss) per share from discontinued operations	0.000	0.000	0.000	0.000
iii	<b>Earnings per equity share</b>				
	Basic earnings (loss) per share from continuing and discontinued operations	-0.155	-0.139	-0.352	-0.340
	Diluted earnings (loss) per share from continuing and discontinued operations	-0.155	-0.139	-0.352	-0.340
31	<b>Debt equity ratio</b>	0.000	0.000	0.000	0.000
32	<b>Debt service coverage ratio</b>	0.000	0.000	0.000	0.000
33	<b>Interest service coverage ratio</b>	0.000	0.000	0.000	0.000
34	<b>Disclosure of notes on financial results</b>	0.000	0.000	0.000	0.000

**Notes:**

- 1 The standalone financial results are being forwarded to the Bombay Stock Exchange (BSE) and are also available on the company's website ([www.indrayani.com](http://www.indrayani.com)).
2. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors in the meeting held on 14th November, 2019. The above financial results are subject to "Limited Review" by the Statutory Auditors of the Company.
3. The Company operates in a single business segment. Hence, no segment wise figures are published.
6. There were no investor complaints pending at the beginning or at the end of the quarter. No compliants were received during the quarter.
5. Previous period figures have been regrouped wherever necessary.

**Date : 14/11/2019**

**Place : Chennai**



**FOR INDRAYANI BIOTECH LIMITED**

A handwritten signature in blue ink, appearing to read 'K. Sayee Sundar'.

**KASIRAMAN SAYEE SUNDAR**

**DIN:01295584**

**Managing Director**

**Statement of Cash Flows for the half year ended 30th September, 2019**

**Amount In Rs. Lakhs**

<b>Particulars</b>	<b>30/Sep/19</b>	<b>30/Sep/18</b>
<b>Cash Flows From Operating Activities:-</b>		
Net Profit Before Taxation	(12.828)	(5.393)
<b>Add:-</b>		
Interest Paid	2.494	-
<b>Less:-</b>		
Interest Income	-	(16.111)
<b>Cash Flow Before Working Capital changes:-</b>	<b>(10.334)</b>	<b>(21.503)</b>
Decrease (Increase) Current Assets	(12.720)	-
(Decrease) Increase Current Liabilities	22.674	0.719
Income Taxes Paid	-	-
<b>Net Cash Flow From Operating Activities</b>	<b>(0.379)</b>	<b>(20.784)</b>
<b>Cash Flow from Investing Activities:-</b>		
<b>Net Cash flow used in Investing Activities</b>	-	-
<b>Cash Flow from Financing Activities:-</b>		
<b>Add:-</b>		
Increase in Borrowings	2.559	4.189
Interest Expenses Notional (As per Ind AS 109)	(2.494)	-
Interest Income Notional (As per Ind AS 109)	-	16.111
<b>Net Cash Flow From Financing Activities</b>	<b>0.065</b>	<b>20.300</b>
<b>Net Increase/(Decrease) in Cash and Cash Equivalents:-</b>		
(Opening Balance)	0.562	1.046
Net Cash Flow during the year	(0.314)	(0.484)
<b>(Closing Balance)</b>	<b>0.248</b>	<b>0.562</b>

1. The cash flow statement has been prepared in accordance with the requirements of Indian Accounting Standard – 7 "Cash Flow Statement" issued by the Institute of Chartered Accountants of India.

2. Cash flows have been reported using the indirect method, whereby the net profit is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments, segregating between cash flows.

3. Significant cash and cash equivalent balances held by the enterprise are available for use by the company.



**For and on behalf of the board**

*K. Jagan Mohan*

**Director**

**DIN: 01295584**

**Date: 14th November, 2019**

**Place: Chennai**